‘Future-proofing’ blood processing for measurement of circulating microRNAs in samples from biobanks and prospective clinical trials by Murray, Matthew et al.
1 
 
‘Future-proofing’ blood processing for measurement of circulating microRNAs in 
samples from biobanks and prospective clinical trials 
Matthew J. Murray
1,2
*, Hannah L. Watson
1
*, Dawn Ward
1
, Shivani Bailey
1
, Marta 
Ferraresso
1
, James C. Nicholson
2
, Vincent J. Gnanapragasam
3
, Benjamin Thomas
4
, 
Cinzia G. Scarpini
1
, Nicholas Coleman
1,5   
* joint first authors 
Correspondence to MJM or NC: mjm16@cam.ac.uk; nc109@cam.ac.uk  
1 
Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, UK. 
2 
Department of Paediatric Haematology and Oncology, Cambridge University Hospitals 
NHS Foundation Trust, Cambridge, UK. 
3 
Academic Urology Group, Department of Surgery, University of Cambridge, UK 
4 
Department of Urology, Cambridge University Hospitals NHS Foundation Trust, 
Cambridge, UK. 
5 
Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, 
Cambridge, UK. 
Conflict of interest statement: the authors have nothing to disclose 
Short title: Blood processing for microRNA quantification 
Keywords: blood; hemolysis, microRNA, plasma, serum 
Words: 4,835 
Figures: Five; Tables: One 
  
2 
 
Abstract 
Background: Quantifying circulating nucleic-acids is an important new approach to cancer 
diagnosis/monitoring.  
Methods: We compared the suitability of serum versus plasma for measuring microRNAs 
using RT-qPCR and assessed how pre-analytical variables that can affect circulating-tumor-
DNA (ctDNA) quantification in plasma also influence microRNA levels.  
Results: Across 62 blood-derived specimens, plasma samples in EDTA, Streck-DNA-plasma 
and Streck-RNA-plasma tubes showed significantly higher Ct values for multiple 
housekeeping microRNAs, compared with serum samples. For the EDTA-plasma tubes, this 
difference was only seen when including the high-speed centrifugation protocol used to 
optimise ctDNA extraction. In plasma samples derived from blood stored at room 
temperature for up to 14 days (conditions that typically apply to samples processed for 
biobanking), levels of endogenous housekeeping microRNAs gradually increased, in parallel 
with the hemolysis-marker hsa-miR-451a, consistent with release from blood cells/platelets. 
It was necessary to normalize levels of the housekeeping microRNAs to those of hsa-miR-
451a, in order to obtain the stable values needed for referencing test microRNA levels.  
Conclusions: Our data indicate that plasma samples prepared for ctDNA extraction are 
suboptimal for microRNA quantification and require the incorporation of multiple data 
normalization steps. For prospective studies designed to measure both microRNAs and 
ctDNA, the most suitable approach would be to obtain both serum (for microRNAs) and 
plasma (for ctDNA). If only plasma can be collected, we recommend an initial low-speed 
centrifugation step, followed by aliquoting the supernatant into parallel samples, one for 
direct microRNA quantification, and the other for a further high-speed centrifugation step to 
optimize ctDNA retrieval. 
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Impact: These recommendations will help ‘future-proof’ clinical studies in which 
quantification of circulating microRNAs is a component. 
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Introduction  
New approaches to cancer diagnosis and/or monitoring are based on detecting nucleic acids 
in blood, including circulating tumor DNA (ctDNA) (1-6) and microRNAs (7,8). Studies 
using ctDNA have almost exclusively been based on plasma, due to the low yield of ctDNA 
retrieved from serum (9,10). Stability of ctDNA in plasma is improved using preservatives, 
for example those in Streck tubes (11-13). However, it is clear that multiple pre-analytical 
variables must be considered in prospective ctDNA-based clinical trials, including time to 
plasma isolation and the types of preservative used (14). 
 
Detection of microRNAs is particularly attractive for many non-epithelial and/or pediatric 
cancers that have a low mutational prevalence (15,16). In testicular malignant germ cell 
tumors (GCTs), for example, mutations occur in less than half of all cases (17). We 
previously identified that microRNAs from the miR-371-373 and miR-302/367 clusters were 
co-ordinately elevated in the serum at the time of malignant GCT diagnosis (18,19) and were 
also sensitive indicators of disease relapse (20). Subsequent studies, from multiple groups, 
have all focussed on serum samples and have confirmed the clinical importance of this novel 
approach to malignant GCT diagnosis (20-30). In consequence, collection of biospecimens 
including blood for further evaluation of microRNA detection has been embedded in multiple 
prospective clinical trials across the spectrum of GCTs. 
 
As future studies of circulating nucleic acids are likely to compare or combine microRNAs 
and ctDNAs for tumor diagnosis/monitoring (31), we sought to address whether plasma 
would also be a suitable medium for detecting circulating tumor-derived microRNAs. If so, 
this would allow combinatorial analysis of microRNAs and ctDNAs from the same sample. 
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We also assessed whether pre-analytical factors that can affect ctDNA analysis in plasma 
samples would also affect microRNA levels in such samples. We compared serum obtained 
using gel separator tubes with plasma derived from EDTA, Streck DNA and Streck RNA 
tubes. For the EDTA tubes, we used two-step centrifugation protocols optimized for ctDNA 
extraction from plasma (32-34). We measured circulating levels of established housekeeping 
microRNAs and assessed effects on microRNA levels of tube type, time to processing, 
centrifugation speed and hemolysis. Based on our findings, we recommend protocols for 
microRNA detection that are optimised for blood samples from biobanks and biological 
studies linked to clinical trials. 
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Materials and Methods  
 
Patient samples 
In total, we analyzed 62 blood-derived specimens. First, we undertook a comparison study, in 
which we comprehensively analyzed 27 specimens collected from a cohort of adult male 
patients (n=7) recruited from a single hospital, via the Cambridge Urology Translational 
Research and Clinical Trials Biorepository (CUTRACT; cases CUB_001 – CUB_007). This 
cohort comprised a group with testicular malignant GCTs (n=5) and a control group with 
non-GCT testicular malignancy (n=2; one relapsed acute myeloid leukemia and one B-cell 
lymphoma). Second, we performed a time-course study of 26 samples from healthy adult 
male subjects (n=2), plus nine specimens from a patient with testicular Leydig cell tumor 
(CUB_008). Details of all specimens, including clinico-pathological information, are 
provided in Supplementary Table S1. All samples were collected with Local Research Ethics 
Committee approval (CUB samples reference 03/018; other samples reference 01/128) and 
informed consent.  
 
Sample collection and processing 
For the comparison study, blood samples were collected immediately prior to orchiectomy. 
The tubes used were: 4.9ml Sarstedt S-Monovette Z-Gel (gel separator serum; ‘GSS’), 9ml 
Sarstedt S-Monovette K3E (EDTA plasma; ‘EP’), 10ml Streck Cell-Free DNA BCT (Streck 
DNA plasma; ‘SDP’) and 10ml Streck Cell-Free RNA BCT (Streck RNA plasma; ‘SRP’). 
Six patients provided samples in all four tubes, while one patient (CUB_003) provided 
samples in three tubes, as an SDP tube was unavailable at the time of patient recruitment. All 
specimens were centrifuged and processed at room temperature within two hours of 
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venepuncture, according to the recommendations of the manufacturers of each tube. There 
was no difference in processing times (average or range) for the different tubes in the 
comparison study. Details of the processing are summarized in Supplementary Table S2. In 
brief, for GSS tubes, the blood was allowed to clot for 30 minutes (min), then centrifuged at 
3,000g for 10min and the separated serum removed from above the gel layer. For EP tubes, 
the blood was centrifuged at 1,600g for 10min, then the separated plasma was aliquoted and 
subjected to a secondary spin of 14,400g for 10min, as per standard protocol conditions for 
preparing plasma for optimal ctDNA analysis (32-34).  For SDP and SRP tubes, the blood 
was initially centrifuged at 300g for 20min and the separated plasma aliquoted into fresh 
tubes, prior to a secondary spin of 5,000g for 10min. For all samples, the final supernatants 
were aliquoted into fresh tubes, then stored immediately at -80
o
C until further analysis. 
 
In the time-course study, we used 2ml SDP tubes, in which levels of RNA recovery  and 
endogenous microRNAs were highly comparable to those in 10ml SDP tubes. Blood samples 
were collected into 1.2ml EP and 2ml SDP tubes, then stored at room temperature for 0, 2, 4, 
7, 10 and 14 days before being processed as above. The samples from one subject (patient 
CUB_008) were also used to study the effects of centrifugation speed on microRNA 
recovery. Of two 1.2ml EP tube samples from this patient, one (EP #1) underwent only the 
first low-speed centrifugation (1,600g) only, whereas the other (EP #2) also underwent the 
second high-speed centrifugation (14,400g). 
 
RNA extraction  
RNA was isolated from 200µl of thawed serum or plasma using the miRNeasy serum/plasma 
kit (Qiagen, Crawley, UK), incorporating MS2 carrier RNA (Roche, Welwyn Garden City, 
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UK) and the exogenous non-human microRNA spike-in, cel-miR-39-3p, as described (20). 
RNA was eluted in 100µl of nuclease-free water. For the comparison study, 750µl of QIAzol 
per sample was used. To assess whether the presence of proteins/nucleases within the 
biospecimens affected RNA retrieval, a subset of samples underwent a further RNA 
extraction that included a proteinase K digestion step. For this, 15µl proteinase K (minimum 
concentration >600mAU/ml; Qiagen) was added to 200µl of each sample, then incubated at 
60˚C for 60 minutes. Subsequently, 750µl of the QIAzol/MS2/cel-miR-39-3p mix was added, 
following which the protocol proceeded as described (20). The same protocols were used in 
the time-course study, except that the volume of QIAzol per sample was increased to 1000µl, 
following an update to the manufacturer’s recommendations. 
 
We also assessed two alternative approaches to RNA extraction from SRP tubes, namely the 
Plasma/Serum RNA Purification Mini Kit (Norgen BioTek Corp, Thorold, ON, Canada) and 
the mirVana PARIS isolation kit (Ambion, Warrington, UK). For the Norgen kit, 200µl of 
circulating sample was used, with the addition of cel-miR-39-3p/MS2 as above, to the lysis 
buffer A. RNA was eluted using 50µl of nuclease-free water. The standard protocol for the 
Norgen plasma/serum kit was also adjusted to include a proteinase K digestion step, where 
20µl of the proteinase K solution described above was added to lysis buffer A, mixed with 
the sample and incubated for 60min at 60˚C. For the mirVana kit, 400µl of circulating sample 
was used, with the addition of 5.6 × 10
8
 copies of cel-miR-39-3p spike-in and MS2 carrier 
RNA to the denaturing solution. In total, 80µl eluate was obtained. 
 
RT-qPCR analysis of microRNA levels 
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In all experiments, levels of circulating microRNAs were detected using our singleplex RT-
qPCR method, as described (20). In short, 5µl of eluted RNA was reverse transcribed using 
the TaqMan miRNA reverse transcription kit (Life Technologies, Paisley, UK), using the 
microRNA-specific stem-loop primer from the relevant TaqMan microRNA assay kit (Life 
Technologies). The final volume of 15µl for each reaction then underwent reverse 
transcription using a GeneAmp PCR System 9700 (Applied Biosystems, Warrington, UK) at 
16˚C for 30 min, 42˚C for 30 min, followed by a final step of 85˚C for 5min. A singleplex 
final PCR was then performed, as per the manufacturer’s instructions, on a Mastercycler 
ep_gradient/S realplex (Eppendorf, Stevenage, UK) at 95˚C for 10min, followed by 45 cycles 
of 95˚C for 15s and 60˚C for one minute, as described (20). 
 
The Ct threshold on the PCR machine was set manually to 2,000 fluorescence units across all 
PCR plates (20). To exclude non-specific amplification, a no-template control (NTC) was 
also run for each assay. None of the test samples had expression levels within 2 Ct values of 
the relevant NTC samples. Samples with Ct values ≥40, or those where the Ct threshold was 
not reached, were considered non-expressing and arbitrarily assigned a Ct value of 40. The 
standard deviations (SD) of Ct values for each set of technical triplicate RT-qPCR reactions 
were calculated. We compared Ct values and SD values between the different sample types. 
We defined Ct values for sample sets as being suboptimal if mean microRNA expression 
values were ≥2 Cts greater than the set with the lowest Ct value (i.e. expression levels were 
≥4-fold lower). We also defined SD values for sample sets as being suboptimal if they were 
≥2. For both Ct and SD assessment, samples that were not suboptimal were deemed to be 
satisfactory. 
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We quantified levels of six microRNAs, namely the exogenous spike-in microRNA cel-miR-
39-3p (20) (added to each sample immediately prior to RNA extraction); the hemolysis-
dependent hsa-miR-451a (35); and the endogenous human reference microRNAs hsa-miR-
23a-3p, hsa-miR-30b-5p, hsa-miR-30c-5p and hsa-miR-191-5p, which were previously 
shown to be readily detectable in both serum and plasma (36,37). In addition, for the time-
course study, we quantified levels of three further endogenous microRNAs, again using 
singleplex RT-qPCR, namely: hsa-miR-130b-3p and hsa-miR-146a-5p, previously shown to 
be present at stable levels in samples regardless of the degree of hemolysis (38); and hsa-
miR-26a-5p, which had also been shown to be stable within the circulation (37). 
 
Hemolysis assessment 
In addition to visual inspection of each serum or plasma sample, hemolysis was assessed 
using two methods (8). First, spectrophotometric analysis of the absorbance of free 
hemoglobin at 414 nm (A414) (38,39) was performed using a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Products, Wilmington, DE, US). Absorbance was tested in 
triplicate and the mean value recorded. Samples were classified as being hemolyzed if A414 
values were >0.2 arbitrary units, as described (38,39). Second, using the RNA extracted from 
the sample, hsa-miR–451a Ct (35) and delta Ct (hsa-miR–23a–3p minus hsa-miR–451a) 
hemolysis values were calculated using singleplex RT-qPCR, as described (20). Delta Ct 
values ≥8 were considered to indicate hemolysis (20). 
 
Statistical analysis 
Statistics were performed using GraphPad Prism 6 software (San Diego, California, US). 
Unless otherwise stated, analyses were performed using either a two-tailed paired t-test (for 
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matched samples) or a two-tailed unpaired t-test with Welch’s correction for unequal 
variance (for unmatched samples). P-values <0.05 were considered significant.  
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Results  
Comparison study of microRNA levels in serum and plasma samples from different 
blood collection tubes 
In the initial comparison study, we assessed levels of six microRNAs in serum samples 
prepared in GSS tubes, versus plasma samples prepared in EP, SDP or SRP tubes. Levels of 
each microRNA were quantified in each sample using technical triplicate RT-qPCR 
reactions. The SD values for each set of triplicate results were very low for all microRNAs 
across the GSS, EP and SDP samples. In contrast, the SD values were much higher for the 
samples in SRP tubes, particularly for hsa-miR-30b-5p and hsa-miR-23a-3p (Supplementary 
Figure S1). 
 
Levels of each individual microRNA in samples from each tube type are shown in Figure 1. 
In summary:  
 For the exogenous normalization microRNA cel-miR-39-3p, Ct values and SDs were 
satisfactory and similar in the GSS, EP and SDP groups (Figure 1, Table 2), 
indicating acceptable RNA extraction and RT-qPCR efficiency. In contrast, these 
parameters were suboptimal in the samples in SRP tubes (Table 1), where Ct values 
were significantly greater than in the EP group (Supplementary Table S3). 
 For the endogenous normalization microRNAs hsa-miR-30b-5p, hsa-miR-30c-5p, 
hsa-miR-191-5p and hsa-miR-23a-3p, Ct values were satisfactory only for serum 
samples in GSS tubes (Figure 1, Table 1). For the EP and SDP plasma samples, Ct 
values were suboptimal and significantly higher than in the samples in GSS tubes 
(Supplementary Table S3). For all four of the normalization microRNAs, the SRP 
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samples showed the highest Ct values, which were significantly greater than in the 
GSS and EP groups (Supplementary Table S3). 
 For the hemolysis-associated microRNA hsa-miR-451a, Ct values were satisfactory 
for the GSS, EP and SDP groups (Figure 1, Table 1), but were again suboptimal in the 
SRP samples, where they were significantly higher than in each of the other sample 
groups (Supplementary Table S3). 
 
We next compared mean Ct values for different microRNAs in each of the four tube types 
(Supplementary Figure S2). Variations in levels of cel-miR-39-3p and those of hsa-miR-30b-
5p (Supplementary Figure S2) were lowest for samples in GSS tubes, which showed very 
tight clustering of Ct values. There was moderate clustering for the EP and SDP samples, but 
very poor clustering for the SRP samples (Supplementary Figure S2). Identical findings were 
also seen for hsa-miR-30c-5p, hsa-miR-191-5p and hsa-miR-23a-3p with cel-miR-39-3p. 
These data indicated that the EP, SDP and SRP tubes resulted in additional technical 
variation, when compared with GSS tubes. 
 
We attempted to develop a method that would allow satisfactory RNA extraction and RT-
qPCR analysis of microRNA levels in plasma from SRP tubes. . Extracting RNA from SRP 
tubes using the Norgen plasma/serum RNA purification kit reduced variability in levels of all 
six microRNAs, compared with RNA extracted from SRP tubes using the Qiagen miRNeasy 
serum/plasma kit (Supplementary Figure S3). However, mean Ct values of all six 
microRNAs in such SRP/Norgen samples remained ≥2 higher than those obtained with RNA 
extracted from GSS tubes using the Qiagen miRNeasy kit. Indeed, for the exogenous 
normalization microRNA cel-miR-39-3p, levels in the SRP/Norgen samples were almost 5 Ct 
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values greater than in the GSS/Qiagen samples. As the eluate from the former was 50µl and 
the latter 100µl, with 5µl from each being used for PCR, this amounted to ~58-fold less 
efficient RNA recovery from the original 200µl serum or plasma samples. Such differences 
in microRNA recovery using the Norgen protocol were not improved by modifications such 
as the incorporation of a proteinase K digestion step . When RNA was extracted from SRP 
tubes using the mirVana PARIS kit, expression levels of each of the six microRNAs tested 
(i.e. those listed in Table 1) were also suboptimal. This large reduction in the efficiency of 
RNA recovery would be expected to limit the overall sensitivity of a PCR assay for detecting 
test microRNA biomarkers (particularly those in low abundance), when compared with a 
serum-based approach. As we were unable to resolve the limitations of SRP tubes for 
quantifying circulating microRNAs, we did not include them in our subsequent analyses. 
 
Time-course study of the effects of blood storage on microRNA levels in plasma 
We studied the effects on microRNA quantification of sample storage in SDP tubes at room 
temperature for up to 14 days, which is the recommended time limit for sample preservation 
prior to plasma extraction for ctDNA quantification. We compared our findings with plasma 
samples stored at room temperature for the same time periods in EP tubes. In total, we 
analyzed 26 separate samples from two healthy subjects, comparing 14 samples in SDP tubes 
with 12 in EP tubes (Supplementary Table S1). 
 
Levels of hemolysis were lower in the SDP samples compared with the EP samples at 
matched time-points, as indicated by sample inspection (Figure 2A) and by 
spectrophotometric measurement of free hemoglobin absorption at 414nm (A414) (Figure 2B). 
Using the standard A414 threshold of >0.2 arbitrary units (38,39), the EP samples were 
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hemolyzed within 1 hour of collection (i.e. the d0 samples). They showed an abrupt increase 
in hemolysis from d4, consistently reaching the upper limit of detection threshold by d14. In 
contrast, hemolysis was not consistently present in the SDP samples until d7. Assessment of 
hemolysis using microRNA delta Ct values (hsa-miR-23a-3p – hsa-miR-451a) indicated 
hemolysis at almost all time-points in both sample types, albeit with occasional variation in 
the values observed (Figure 2C). 
 
Next, we investigated changes in levels of individual microRNAs in plasma obtained from 
the SDP versus the EP tubes over the 14 day time-course (20). As cel-miR-39-3p was spiked-
in immediately prior to RNA extraction for each time-point, it was not surprising that we saw 
no difference in levels of this microRNA (Figure 3A). In contrast, levels of all six 
endogenous housekeeping microRNAs tested [hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-
191-5p (Figure 3); hsa-miR-26a-5p, hsa-miR-130b-3p, hsa-miR-146a-5p (Supplementary 
Figure S4)] all showed similar gradual reductions in Ct values over the time-course, 
indicating gradual increases in expression levels in the blood from which the plasma samples 
were derived. Similar changes were seen in the red blood cell derived microRNA hsa-miR-
451a, suggesting that the elevations in endogenous housekeeping microRNAs were related to 
hemolysis. Indeed, normalization of levels of the six endogenous housekeeping microRNAs 
to those of hsa-miR-451a resulted in stabilization of microRNA measurements over the time-
course (Figure 3 and Supplementary Figure S4). These findings were confirmed in a further 
set of SDP samples obtained from a patient with testicular Leydig cell tumor (CUB_008; 
Supplementary Table S1, Supplementary Figure S5). 
 
Comparison of methods of hemolysis assessment in plasma samples 
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When quantifying test microRNAs, it is important also to measure hemolysis, in order to 
exclude any confounding effects of microRNAs released from blood cells (40). We 
investigated whether previously established parameters for measuring hemolysis in serum 
using microRNA quantification (8,20,41) could also be applied to the plasma samples in our 
study. The established delta Ct (hsa-miR-23a-3p - hsa-miR-451a) hemolysis method was 
applied to the samples from the comparison study in which there was no evidence of 
hemolysis by spectrophotometry (n=20) (Figure 4A). A delta Ct value indicating hemolysis 
(delta Ct >8) was seen in only one of seven GSS serum samples but in six of seven EP and 
five of six SDP plasma samples (Figure 4B). The false positive results in the plasma samples 
were attributable to significantly lower detection levels (higher Ct values) of the endogenous 
housekeeping gene hsa-miR-23a-3p in the EP and SDP samples, compared with the GSS 
samples (p=0.018 and p=0.0002, respectively) (Figure 1E, Supplementary Table S3). 
 
When analysing 32 available EP and SDP samples from across the comparison and time-
course studies, only 20 (62%) were classified as hemolyzed by spectrophotometry (Figures 
4C/D), whereas 30 (94%) were classified as hemolyzed by using the delta Ct value (Figure 
4D). The samples that were classified as hemolyzed by spectrophotometry showed higher 
delta Ct values (p=0.009, unpaired t-test; Figure 4D) and lower raw Ct values for hsa-miR-
451a (p<0.0001, unpaired t-test; Figure 4C), compared with the samples that were classified 
as non-hemolyzed by spectrophotometry. The A414 absorbance values strongly fitted a non-
linear association with the raw hsa-miR-451a Ct values (R
2
=0.818; Figure 4E). However, 
they only weakly fitted a non-linear association with the delta Ct (hsa-miR-23a-3p – hsa-
miR-451a) values (R
2
=0.224; Figure 4F), in keeping with the limited accuracy of hsa-miR-
23a-3p quantification in the plasma samples. The dynamic range of the A414 absorbance 
values was greater than those of the raw hsa-miR-451a values (Figure 4E) and delta Ct (hsa-
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miR-23a-3p – hsa-miR-451a) values (Figure 4F), further indicating the limited utility of 
microRNA quantification for assessing hemolysis in the plasma samples. 
 
Effect of centrifugation speed on microRNA levels in plasma 
We sought to determine whether the differences observed between the serum and plasma 
samples were due to inherent features of the sample types or to the different processing 
protocols used. We examined the effect of centrifugation speed on microRNA recovery from 
plasma, using samples extracted from EP tubes, in comparison with serum samples prepared 
from GSS tubes. We first used samples from patient CUB_008, to compare the effect of a 
single low-speed centrifugation step (1,600g; EP #1) with the standard dual centrifugation 
that is typically used when preparing plasma for ctDNA analysis (1,600g then 14,400g; EP 
#2). The mean expression level of five microRNAs (namely hsa-miR-30b-5p, -30c-5p, -191-
5p, -23a-3p and -451a) was significantly lower (higher Ct values) in the EP #2 sample, 
compared with the EP #1 (p=0.03) and the GSS sample (p=0.01) (Figure 5A). When 
analyzing each microRNA individually, levels were also lower in the EP #2 sample compared 
with the EP #1 and GSS samples (Figure 5B). There were no differences between the EP #1 
and GSS samples in the mean expression levels (Figure 5A), nor in the levels of each 
microRNA individually (Figure 5B). 
 
We extended these findings by interrogating data from a published global microRNA 
profiling study of EP samples (from breast cancer patients) that had been centrifuged at 
various speeds (42). For the 106 microRNAs with Ct values <35 [listed in (42)], mean levels 
were significantly lower in EP samples that underwent high-speed centrifugation (10,000g), 
compared with EP samples that underwent low-speed centrifugations (either 2,000g or 
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1,000g; p<0.001 for both comparisons) (Figure 5C). There was no significant difference in 
mean microRNA expression levels between the 1,000g and 2,000g centrifugation samples 
(Figure 5C). Levels of individual microRNAs were again lower (higher Ct values) in the 
samples that had received high-speed centrifugation, compared with the low-speed samples 
(Figure 5D). The differences in expression levels were particularly large for the three 
endogenous housekeeping genes hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-191-5p, but 
were also seen for hsa-miR-451a (data on hsa-miR-23a-3p levels were not available). Across 
the 106 microRNAs, high-speed centrifugation had a highly unpredictable effect on 
microRNA levels compared with low-speed centrifugation (Figure 5E). Ct values were 
almost always higher in the high-speed samples, albeit with rare exceptions (Figure 5E). The 
difference in expression levels ranged from zero to >8 Ct values, with a modal difference of 
2-4 Ct values (Figure 5F). 
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Discussion 
Biospecimens collected by tissue banks increasingly include blood-derived samples for 
quantification of circulating nucleic acids. Most effort to date has focussed on studying pre-
analytical variables that affect ctDNA quantification (11-14). Here, we sought to establish 
how such variables affect microRNA levels and to generate a recommended protocol for 
collecting and processing blood-derived biospecimens, in order to maximise the yield of 
recovered microRNAs. Our comparison study demonstrated that serum samples were better 
suited for microRNA studies than the plasma samples tested, as the latter showed greater 
technical variation, with consistently lower levels of endogenous housekeeping microRNAs. 
The differences we observed were not attributable to the method used for microRNA 
extraction, as the Qiagen miRNeasy serum/plasma kit was independently demonstrated to 
provide the highest yield of microRNAs from plasma samples (42). The difference between 
serum and plasma from EP tubes (Figure 1) is likely to relate to the two-spin processing used 
for preparing the latter, a method that is typically adopted to optimize ctDNA extraction. 
Samples processed from EP tubes with a low-speed centrifugation step only did not show 
significant differences in microRNA levels compared with serum samples (Figure 5A/B), 
indicating that plasma is not necessarily an inferior substrate for microRNA extraction, if 
appropriate protocols are adopted. We found Streck RNA (SRP) tubes to be unsuitable for 
microRNA studies, despite using various RNA extraction methods and protocol 
modifications, including the incorporation of a proteinase K digestion step. 
 
The uniform clotting process inherent in preparing serum removes a large proportion of 
protein from a whole blood sample. One practical benefit of this is that the layer of protein 
obtained when extracting RNA from serum is relatively small. While endogenous 
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microRNAs are released into the serum during the clotting process, for example from 
platelets, the overall pipeline involved in serum processing is straightforward, and most 
importantly, provides very similar levels of endogenous housekeeping microRNAs across 
samples. As plasma lacks the clotting step, the protein layer obtained during RNA extraction 
is large, leading to smaller yields of supernatant. This may necessitate repeated sample 
processing in order to obtain adequate volumes of eluate for microRNA quantification, 
potentially exacerbating the technical variations in measuring microRNA levels in plasma. 
 
A further consideration when evaluating blood-derived biospecimens is the stability of 
microRNAs during prolonged storage of unprocessed blood. Such conditions typically apply 
to the blood specimens from which plasma samples are obtained for biobanking, for example 
those from a multi-center clinical trial. In plasma samples derived from blood stored over a 
period of up to 14 days at room temperature, we observed increases in levels of the 
endogenous housekeeping microRNAs hsa-miR-30b-5p, hsa-miR-30c-5p and hsa-miR-191-
5p. These were associated with parallel changes in the hemolysis marker hsa-miR-451a, 
suggesting that the microRNAs were likely to have been released into the plasma from red 
blood cells and/or platelets, either through active shedding or passively as a result of 
hemolysis. As a result, stabilization of the levels of housekeeping microRNAs in plasma 
samples over the 14 day time-course required correction for levels of hsa-miR-451a. 
 
An additional consequence of the variations in levels of housekeeping microRNAs in the 
plasma samples studied is that hemolysis could not reliably be indicated by the delta Ct (hsa-
miR-23a-3p - hsa-miR-451a) microRNA quantification method. This is an important contrast 
with serum samples, where hemolysis can be quantified accurately using this microRNA 
21 
 
method (8,20). In our comparison study, the majority of the plasma samples were falsely 
classified as showing hemolysis by the delta Ct method. This was predominantly due to 
reduced levels of the housekeeping microRNA hsa-miR-23a-3p, rather than alterations in the 
levels of the direct hemolysis marker hsa-miR-451a. In our time-course study, delta Ct 
hemolysis levels in the plasma samples increased then plateaued during a period of ongoing 
hemolysis (which was indicated by sample inspection and spectrophotometric measurement 
of hemoglobin absorbance). Normalization of hsa-miR-23a-3p levels to those of hsa-miR-
451a, as required for other housekeeping microRNAs in stored plasma samples, would not be 
appropriate when using the delta Ct (hsa-miR-23a-3p - hsa-miR-451a) method for hemolysis 
quantification.  
 
Processing of plasma samples for ctDNA quantification typically involves a double 
centrifugation process, which includes a high-speed (≥10,000g) second spin, designed to 
remove background genomic DNA contamination (32-34). Our experimental findings and re-
analysis of published data (42) show that such a two-step process significantly alters the 
profile of circulating microRNAs detected in plasma samples, compared with plasma samples 
processed by low-speed centrifugation only and also with serum samples. These findings are 
consistent with a previous global microRNA profiling study showing that the two-step 
method, including high-speed centrifugation, resulted in lower microRNA levels in plasma 
when compared with serum (43). Our analyses indicate that the alterations in plasma 
microRNA levels produced by high-speed centrifugation are highly variable and 
unpredictable. The microRNAs affected most may predominantly be present in relatively 
large structures in the plasma, such as platelets or large extracellular vesicles, that are 
removed by the high-speed centrifugation step (42). 
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Taken together, our data allow us to make recommendations for the design of biological 
studies linked to clinical trials, and/or retrospective studies of samples in biorepositories, 
where quantification of circulating microRNAs is a requirement. Our findings indicate that 
serum is the optimum biospecimen for quantifying circulating microRNAs, as it is subject to 
the least pre-analytical technical variation. The optimal approach for studies measuring both 
circulating microRNAs and ctDNA would therefore be to collect both serum (for 
microRNAs) and plasma (for ctDNA). If only plasma can be collected, then immediate 
processing is recommended, in order to avoid the technical variations that affect microRNA 
levels after storage and/or transport of plasma at room temperature. We further recommend 
that such plasma processing should involve a low-speed centrifugation step only, followed by 
aliquoting the supernatant into parallel samples prior to storage at -80
o
C. Such aliquots could 
then be used directly for microRNA quantification, or subjected to a further high-speed 
(≥10,000g) centrifugation step to optimise ctDNA retrieval (42).  
 
For retrospective analysis of microRNA levels in plasma samples from biorepositories, 
particularly those prepared for ctDNA extraction, we recommend normalization of 
housekeeping microRNA levels using cel-miR-39-3p (correcting for technical differences in 
RNA recovery) and hsa-miR-451a (correcting for the effects of hemolysis), and also the use 
of multiple housekeeping microRNAs for referencing the levels of test microRNAs. These 
steps will improve the likelihood of avoiding biologically inconsistent or even contradictory 
results, as has recently been highlighted for various urological tumors (7). Despite these 
steps, our data indicate that the results of retrospective microRNA quantification work in 
such plasma samples should be interpreted with caution. 
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In our opinion, these technical considerations are of vital importance to the design of future 
clinical trials and/or retrospective studies of biobank samples. Our recommendations are 
practicable and scalable. They will help future-proof clinical studies in which quantification 
of circulating microRNAs is a component. 
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Legends to Figures and Tables 
 
Figure 1. Levels of individual microRNAs in samples from the four types of blood 
collection tube in the comparison study. The plots show Ct values for: A) the exogenous 
non-human spike-in microRNA cel-miR-39-3p; B)-C) the microRNAs hsa-miR-23a-3p and 
hsa-miR-451a used for hemolysis assessment; and D)-F) the three established endogenous 
housekeeping microRNAs hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-191-5p. Key to blood 
collection tubes: GSS = gel separator serum (green boxes); EP = EDTA plasma (blue); SDP = 
Streck DNA plasma (red); SRP = Streck RNA plasma (grey). Bar = median, box = 
interquartile range; whiskers = full range of data. 
 
Figure 2. Levels of hemolysis in plasma samples from the time-course study. A) 
Appearance of the plasma samples derived from the SDP and EP tubes taken from two 
healthy control subjects (CONT_001 and CONT_002) at the six time-points [day (d) 0, d2, 
d4, d7, d10 and d14]. The darker the sample color, the greater the degree of hemolysis. B) 
Spectrophotometric analysis of the plasma samples in A), showing mean absorbance of free 
hemoglobin at 414nm (A414). The lower dotted line indicates the threshold (0.2) above which 
samples were classified as hemolyzed, while the upper dotted line (3.0) indicates the upper 
limit of detection of the spectrophotometer. C) Hemolysis assessment by delta Ct (hsa-miR-
23a-3p – hsa-miR-451a) values. The dotted line indicates the Ct value threshold (8) above 
which samples were classified as hemolyzed. Key: EP = EDTA plasma (blue lines); SDP = 
Streck DNA plasma (red lines). Error bars = SD. 
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Figure 3. MicroRNA levels in plasma samples from the time-course study. Graphs show 
Ct values for the plasma samples derived from the SDP and EP tubes taken from two healthy 
control subjects (CONT_001 and CONT_002) at the six time-points [day (d) 0, d2, d4, d7, 
d10 and d14]. Panels A)-F) show raw Ct values (solid lines) for: A) the exogenous non-
human spike-in microRNA cel-miR-39-3p; B)-C) the microRNAs hsa-miR-23a-3p and hsa-
miR-451a used for hemolysis assessment; and D-F) the three established endogenous 
housekeeping microRNAs hsa-miR-30b-5p, hsa-miR-30c-5p and hsa-miR-191-5p. Panels 
G)-I) show the hemolysis-corrected Ct values (dotted lines) for the three endogenous 
housekeeping microRNAs shown in D)-F). Key: EP = EDTA plasma (blue lines); SDP = 
Streck DNA plasma (red lines). Note that error bars are not visible as they fall within each 
respective data-point. 
  
Figure 4. Comparison of methods of hemolysis quantification. A)-B) Measurement of 
hemolysis in samples from the comparison study using: mean absorbance of free hemoglobin 
at 414nm (A414), as assessed by spectrophotometry (A); and delta Ct (hsa-miR-23a-3p - hsa-
miR-451a) values (B). C)-D) Raw Ct hsa-miR-451a values (C) and delta Ct (hsa-miR-23a-3p 
- hsa-miR-451a) values (D) in 32 EP and SDP samples from both the comparison and time-
course studies, identified by spectrophotometry as non-hemolyzed (yellow box; A414 values 
≤0.2) or hemolyzed (orange box; A414 values >0.2). E)-F) Associations of raw Ct hsa-miR-
451a values (E) and delta Ct (hsa-miR-23a-3p - hsa-miR-451a) values (F) with A414 
absorbance for the 32 plasma samples analyzed in C) and D), including the lines of best fit. 
Key: GSS = gel separator serum (green box); EP = EDTA plasma (blue); SDP = Streck DNA 
plasma (red). Bar = median, box = interquartile range; whiskers = full range of data. 
Hemolysis thresholds are indicated by the dotted lines, as defined in the legend to Figure 2. 
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Figure 5. Effect of centrifugation speed on microRNA levels in plasma samples. A) Ct 
values (cel-miR-39-3p-normalized) for five endogenous microRNAs (hsa-miR-30b-5p, hsa-
miR-30c-5p, hsa-miR-191-5p, hsa-miR-23a-3p and hsa-miR-451a) in the GSS, EP #1 and EP 
#2 samples from patient CUB_008; B) Individual Ct values (cel-miR-39-3p-normalized) for 
the five endogenous microRNAs assessed in A). Key for A)-B): GSS = gel separator serum 
(green box); EP #1 = EDTA plasma (low-speed centrifugation only, light blue); EP #2 = 
EDTA plasma (including high-speed centrifugation, blue). C) Mean Ct values for 106 
endogenous microRNAs in EP samples processed using different centrifugation speeds (42). 
D)-E) Individual raw Ct values for four of the five endogenous microRNAs from panels A) 
and B) (D) and all 106 microRNAs (E) in EP samples processed using different 
centrifugation speeds. F) Differences in Ct values for all 106 microRNAs in EP samples 
centrifuged at 10,000g vs. 2,000g. Key for C)-F): EP 1,000g = EDTA plasma samples with 
low-speed centrifugation at 1,000 g (light-blue); EP 2,000g = EDTA plasma samples with 
low-speed centrifugation at 2,000 g (mid-blue); EP 10,000g = EDTA plasma samples with 
high-speed centrifugation at 10,000 g (dark-blue). In panels A) and C), bar = median, box= 
interquartile range; whiskers = full range of data. 
 
Table 1. MicroRNA levels in each of the four blood collection tubes from the 
comparison study. Comparison of Ct values and SD values between the different sample 
types. Ct values for sample sets were defined as being suboptimal if mean microRNA 
expression values were ≥2 Cts greater than the set with the lowest Ct value. SD values for 
sample sets were defined as suboptimal if they were ≥2. For both Ct and SD assessment, 
samples that were not suboptimal were deemed to be satisfactory. Key to blood collection 
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tubes: GSS = gel separator serum; EP = EDTA plasma; SDP = Streck DNA plasma; SRP = 
Streck RNA plasma. 
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Table 1 
 
 
microRNA Role GSS EP SDP SRP 
Mean Ct value SD Conclusion Mean Ct value SD Conclusion Mean Ct value SD Conclusion Mean Ct value SD Conclusion 
cel-miR-39-3p Exogenous normalization 21.43 0.49 Satisfactory 21.13 0.85 Satisfactory 20.91 1.19 Satisfactory 25.23 4.29 Suboptimal 
hsa-miR-30b-5p Endogenous normalization 27.16 0.90 Satisfactory 29.57 1.18 Suboptimal 29.44 1.04 Suboptimal 34.41 4.45 Suboptimal 
hsa-miR-30c-5p Endogenous normalization 27.77 0.68 Satisfactory 29.93 1.16 Suboptimal 29.73 1.11 Suboptimal 33.78 4.16 Suboptimal 
hsa-miR-191-5p Endogenous normalization 25.91 0.72 Satisfactory 28.76 1.00 Suboptimal 30.02 1.49 Suboptimal 32.74 3.10 Suboptimal 
hsa-miR-23a-3p Endogenous normalization 
(hemolysis) 
28.84 0.89 Satisfactory 30.26 1.10 Satisfactory 32.47 0.86 Suboptimal 39.20 0.84 Suboptimal 
hsa-miR-451a Hemolysis assessment 21.73 0.96 Satisfactory 21.55 0.72 Satisfactory 23.50 1.27 Satisfactory 32.90 4.30 Suboptimal 
 
 
 
 
 
 
